Company: ZVRA
Filing Date: 2025-03-31
Form Type: DEFA14A
Source: 0001193125-25-068941
Chunk: 5

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: DEFA14A
Chunk 5
---
 15, 2024), Corey M. Watton (May15, 2024), Douglas W. Calder (May15, 2024), Tamara A. Favorito (May 15, 2024), Wendy L. Dixon (May 15, 2024), John B. Bode (May15, 2024), Rahsaan W. Thompson (June25, 2024), John B. Bode (July 15, 2024), Thomas Anderson (July 16, 2024), R. LaDuane Clifton (July 17, 2024), Corey M. Watton (October 16, 2024), Neil F. McFarlane (February 3, 2025), R. LaDuane Clifton (February3, 2025), Joshua Schafer (February3, 2025), Rahsaan W. Thompson (February 3, 2025), Neil F. McFarlane (February 10, 2025), Neil F. McFarlane (February 14, 2025), R. LaDuane Clifton (February 14, 2025), Joshua Schafer (February 14, 2025), John B. Bode (March 21, 2025), and Adrian W. Quartel (March 27, 2025).These documents are available free of charge at the SEC’s website at . Copies of the documents are also available free of charge by accessing Zevra’s investor relations website at
.

Contacts

For investor inquiries

Nichol Ochsner

+1 (732) 754-2545

nochsner@zevra.com

For media inquiries

FTI Consulting

Pat Tucker / Tanner Kaufman

zevratherapeutics@fticonsulting.com